Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | AHCY | P23526 | 3/20 | 0.53 |
| ▸ | ADA | P00813 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 2/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021398 | 1.00 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL16359945 | 1.00 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D | |
| Iodide SCHEMBL16244633 | 0.99 | POLB (0.66) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL15617973 | 0.90 | POLB (0.68) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL6756462 | 0.90 | POLB (0.68) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL25393800 | 0.89 | ENPP1 (0.68) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL15798579 | 0.89 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL8811716 | 0.89 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL28121854 | 0.89 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D | |
| SCHEMBL25392522 | 0.89 | POLB (0.67) | POLBENPP1P2RY1HIF1APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| CN-114076805-A | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-02-22 | — | — | CN | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| US-20040229261-A1 | Comprises nucleotide sequences probes and primers which hybridize flaviviral 3' untranslated regions for use as diagnostic tools in viral disease detection/infection; point mutations | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2004-11-18 | — | — | US | claimed |
| EP-4396207-A2 | POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS | The University of Chicago (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3215617-B1 | SYSTEMS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE INC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4359527-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024086659-A2 | COMPOSITION AND METHODS FOR DETECTING ADENINE MODIFICATIONS | THE UNIVERSITY OF CHICAGO (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240110179-A1 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | EDITAS MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0675966-A4 | — | — | 1995-11-22 | — | — | EP | disclosed |
| EP-0675966-A1 | NOVEL OLIGONUCLEOTIDE ARRAYS AND THEIR USE FOR SORTING, ISOLATING, SEQUENCING, AND MANIPULATING NUCLEIC ACIDS | THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1993017126-A1 | NOVEL OLIGONUCLEOTIDE ARRAYS AND THEIR USE FOR SORTING, ISOLATING, SEQUENCING, AND MANIPULATING NUCLEIC ACIDS | THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. (US) | 1993-09-02 | — | — | WO | disclosed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | POLB 1956/4885ENPP1 538/4885P2RY1 157/4885 |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | DCLRE1B, MPG, UNG | POLB 214/4885ENPP1 1080/4885P2RY1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.